Detalhe da pesquisa
1.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Future Oncol
; 18(32): 3563-3572, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36382554
2.
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Breast Cancer Res Treat
; 187(2): 467-476, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33748921
3.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(4): 519-530, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171426
4.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
J Clin Oncol
; 39(13): 1448-1457, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539215
5.
Topoisomerase 2 is dispensable for the replication and segregation of small yeast artificial chromosomes (YACs).
PLoS One
; 9(8): e104995, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25115861
6.
DNA methylation-mediated silencing of PU.1 in leukemia cells resistant to cell differentiation.
Springerplus
; 2: 392, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24010046